[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 73
Citations 0
In This Issue of JAMA Otolaryngology
June 2016


JAMA Otolaryngol Head Neck Surg. 2016;142(6):511. doi:10.1001/jamaoto.2015.1809

An important end point for many cancer chemotherapy trials is the development of toxic effects. Standard data collection forms capture these data from clinicians but not from patients. Falchook et al examined toxicity data reported by clinicians and patients from a phase 2 clinical trial of deintensified chemoradiotherapy for oropharyngeal cancer. They found a significant decline in agreement between clinician and patient reports as toxic effects developed and that clinicians reported lower severity of toxic effects than did patients. This suggests that the inclusion of patient-reported symptoms and toxic effects can improve the quality of clinical trials and patient care. Worden provides an Invited Commentary.

First Page Preview View Large
First page PDF preview
First page PDF preview